Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science Spotlight: Advances in RSV and hMVP vaccines 

BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates

By Danielle Golovin, Senior Biopharma Analyst
December 5, 2024 12:01 AM UTC

A pair of studies by independent groups revealed advances in respiratory syncytial virus (RSV) and human metapneumovirus (hMVP) vaccines. 

In the first study, published in Nature Microbiology, Johnson & Johnson (NYSE:JNJ) developed an RSV vaccine that prevents lower respiratory tract infections similar to current RSV vaccines, but without inducing potentially problematic antibodies against a vaccine design component...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cullgen Inc.

Gsk plc

Icahn School of Medicine at Mount Sinai

Johnson & Johnson

Scripps Research

Uvax Bio LLC